Companies › Alpheus Medical
2 active drug programs in 4 registered trials: 2 Phase 1, 2 Phase 2; Oncology; next expected readout Oct 2027.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| 5-ALA HCl | – | Phase 2 | Glioblastoma; Glioblastom WHO Grade 4 | Oct 2027 |
| LIDU ultrasound Low-intensity, defocused ultrasound device used to activate porphyrin metabolites for tumo | – | Phase 1 | Glioblastom WHO Grade 4 | Oct 2027 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT07862647 | LIDU ultrasound | Phase 1 | Glioblastom WHO Grade 4 | Oncology | Oct 2027 |
| NCT07862647 | 5-ALA HCl | Phase 1 | Glioblastom WHO Grade 4 | Oncology | Oct 2027 |
| NCT07225621 | 5-ALA HCl | Phase 2 | Glioblastoma | Oncology | Dec 2027 |
| NCT07225621 | 5-ALA HCl | Phase 2 | Glioblastoma | Oncology | Dec 2027 |
No annotated target.
–
Norroy Bioscience Beijing Yongtai Ruike Biotechnology Company Tianjin ConjuStar Biologics Han Xu, M.D., Ph.D., FAPCR, Sponsor-Investigator, IRB Chair Imbioray (Hangzhou) Biomedicine
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.